University Cancer & Blood Center

Clinical Trials for Bladder Cancer

1403-0002

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091 (Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors. View details.


Learn more about Bladder Cancer >

Our Affiliations

The Cancer FoundationNCIACHC Accredited

We’re Here to Help! Click Below to Get Started

Contact Us Now